Published in Biochem Pharmacol on October 01, 1980
N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A (1984) 3.09
Contribution of mitochondrial GSH transport to matrix GSH status and colonic epithelial cell apoptosis. Free Radic Biol Med (2007) 1.81
Inhibition of relaxations to nitrergic stimulation of the mouse anococcygeus by duroquinone. Br J Pharmacol (1995) 1.04
Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest (1997) 1.04
Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One (2010) 1.03
DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates. Biochem J (1989) 0.98
Enzymology of bioreductive drug activation. Br J Cancer Suppl (1996) 0.94
Reduction of ubiquinone in membrane lipids by rat liver cytosol and its involvement in the cellular defence system against lipid peroxidation. Biochem J (1995) 0.80
Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase. Biochem J (1992) 0.80
Selective inhibition of adenylate cyclase in bovine cortex by quinones: a novel cellular substrate for quinone cytotoxicity. Biochem J (1994) 0.77
Genetic evidence for NAD(P)H:quinone oxidoreductase 1-catalyzed quinone reduction on passage through the mouse pulmonary circulation. Am J Physiol Lung Cell Mol Physiol (2011) 0.76
Structure-activity relationships in the free-radical metabolism of xenobiotics. Environ Health Perspect (1985) 0.76
Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer (1983) 0.76
Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest (1988) 6.29
Thioredoxin reductase. Biochem J (2000) 3.47
Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure (1996) 2.07
Prospective, randomized trial of survivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscitation endpoints in severe trauma. J Trauma (1995) 1.86
Multicenter trial of a new thoracic electrical bioimpedance device for cardiac output estimation. Crit Care Med (1994) 1.68
Binding of catecholamines to connective tissue and the effect upon the responses of blood vessels to noradrenaline and to nerve stimulation. J Physiol (1973) 1.63
Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. Crit Care Med (1993) 1.59
Reliability of clinical monitoring to assess blood volume in critically ill patients. Crit Care Med (1984) 1.52
Cloning and sequencing of a human thioredoxin reductase. FEBS Lett (1995) 1.50
Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. J Immunol (1988) 1.49
Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc (1988) 1.49
Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer (1990) 1.48
Unreliability of blood pressure and heart rate to evaluate cardiac output in emergency resuscitation and critical illness. Crit Care Med (1993) 1.48
Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res (1997) 1.47
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46
Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest (1992) 1.44
Hemodynamic and oxygen transport changes following endotracheal suctioning in trauma patients. Nurs Res (1991) 1.43
Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc (1988) 1.43
3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem (2000) 1.38
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res (1996) 1.33
Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem (1994) 1.33
Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failure. Crit Care Med (1988) 1.32
Regulation of human thioredoxin reductase expression and activity by 3'-untranslated region selenocysteine insertion sequence and mRNA instability elements. J Biol Chem (1999) 1.30
Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis (1990) 1.28
Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol (1998) 1.22
Sequence of physiologic patterns in surgical septic shock. Crit Care Med (1993) 1.21
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res (1995) 1.20
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol (2000) 1.20
Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res (1997) 1.17
Comparison of measurements of cardiac output by bioimpedance and thermodilution in severely ill surgical patients. Crit Care Med (1986) 1.16
Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ (1995) 1.13
Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60 --> asparagine mutant. Biochemistry (1997) 1.10
Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry (1993) 1.09
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys (2001) 1.09
Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett (1999) 1.09
Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J Med Chem (2001) 1.06
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. J Biol Chem (1990) 1.05
Increased incidence of cardiac contusion in patients with traumatic thoracic aortic rupture. Ann Surg (1988) 1.05
Multicomponent noninvasive physiologic monitoring of circulatory function. Crit Care Med (1988) 1.04
Relationship between supranormal circulatory values, time delays, and outcome in severely traumatized patients. Crit Care Med (1993) 1.04
The binding of catecholamines to human serum proteins. Biochem Pharmacol (1975) 1.02
Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res (1997) 1.02
Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol (1985) 1.01
Clinical and radiographic indications for aortography in blunt chest trauma. J Vasc Surg (1987) 1.01
The effects of pargyline on overflow of transmitter and uptake of noradrenaline in the cat spleen. Br J Pharmacol (1973) 1.00
Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res (1998) 1.00
Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis (1990) 0.99
Some properties of a preparation of rat colon perfused in vitro through the vascular bed. J Physiol (1971) 0.99
Effect of a single oral dose of methanol, ethanol and propan-2-ol on the hepatic microsomal metabolism of foreign compounds in the rat. Biochem J (1975) 0.98
Diagnosis of traumatic thoracic aortic rupture: a 10-year retrospective analysis. Ann Thorac Surg (1989) 0.97
Clinical trial of an algorithm for outcome prediction in acute circulatory failure. Crit Care Med (1982) 0.97
Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat. Biochem Pharmacol (1982) 0.96
Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. Cancer Res (2001) 0.96
Tachyphylaxis to ethacrynic acid in the isolated atrium of guinea-pig and its relation to noradrenaline stores. Br J Pharmacol (1978) 0.96
Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. Arch Biochem Biophys (1981) 0.96
Fluid therapy in emergency resuscitation: clinical evaluation of colloid and crystalloid regimens. Crit Care Med (1981) 0.95
PI-3-Kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets (2011) 0.95
The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta (1994) 0.95
Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells. Mol Pharmacol (1981) 0.95
Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci U S A (1994) 0.94
Clinical trial of survivors' cardiorespiratory patterns as therapeutic goals in critically ill postoperative patients. Crit Care Med (1982) 0.94
An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. Cancer Res (1995) 0.94
Hemodynamic and oxygen transport effects of dobutamine in critically ill general surgical patients. Crit Care Med (1986) 0.94
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73-->Ser mutation. Biochem Pharmacol (1996) 0.93
Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol (1999) 0.91
Calorimetric study of microsomal membrane. J Biol Chem (1977) 0.91
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation. Invest New Drugs (1988) 0.90
Therapy of critically ill postoperative patients based on outcome prediction and prospective clinical trials. Surg Clin North Am (1985) 0.90
The accumulation and metabolism of (-)-noradrenaline by cells in culture. Br J Pharmacol (1973) 0.89
DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer (1989) 0.89
Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des (1997) 0.89
Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. Cancer Res (1986) 0.89
Comparison of the relative effectiveness of colloids and crystalloids in emergency resuscitation. Am J Surg (1981) 0.88
Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res (1993) 0.88
The effects of exercise and adrenaline infusion upon the blood levels of propranolol and antipyrine in the horse. J Pharmacol Exp Ther (1978) 0.88
Incomplete hydrolysis of the calcium indicator precursor fura-2 pentaacetoxymethyl ester (fura-2 AM) by cells. Anal Biochem (1988) 0.88
Evaluation of fluid therapy in adult respiratory failure. Crit Care Med (1981) 0.87
Redox active disulfides: the thioredoxin system as a drug target. Oncol Res (1997) 0.87
Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog. Cancer Chemother Pharmacol (1988) 0.86
Comparison of hemodynamic and oxygen transport effects of dopamine and dobutamine in critically ill surgical patients. Chest (1989) 0.86
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat Rep (1986) 0.86
Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol (1992) 0.86
Phase I and pharmacokinetic studies of DON. Cancer Treat Rep (1982) 0.86
Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev (1983) 0.86
Oxygen transport measurements to evaluate tissue perfusion and titrate therapy: dobutamine and dopamine effects. Crit Care Med (1991) 0.86
Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res (1979) 0.85
Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res (1999) 0.85
The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer. Biochem Biophys Res Commun (1997) 0.85
Therapy of shock based on pathophysiology, monitoring, and outcome prediction. Crit Care Med (1990) 0.85
Pathophysiology of adult respiratory distress syndrome after sepsis and surgical operations. Crit Care Med (1985) 0.84
Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochem Biophys Res Commun (2000) 0.84
Effect of serum albumin upon the response of the rat isolated superfused anococcygeus muscle to catecholamines and to nerve stimulation. J Pharm Pharmacol (1974) 0.84
Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des (2000) 0.84
Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochem Biophys Res Commun (2003) 0.83
Metabolism and covalent binding of [14C]toluene by human and rat liver microsomal fractions and liver slices. Drug Metab Dispos (1991) 0.83
Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol (1992) 0.83
Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res (1990) 0.83
Assessment of intestinal and renal perfusion using surface oximetry. Crit Care Med (1986) 0.83
An uptake mechanism for L-noradrenaline in the cat spleen, associated with the nerves but distinct from uptake. J Physiol (1974) 0.83
3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J Med Chem (1998) 0.83